Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.

Journal article

Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.

Authors: Lacy, MD; Maguire, J; Barcus, M; Ling, J; Bangs, M

• Publication status: Published
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
• Volume: 35
• Issue: 9
• Pages: e92-e95
• Publication date: 2002-11-01
• DOI: 10.1086/343750
• EISSN: 1537-6591
• ISSN: 1058-4838
• Language: English
• Keywords: Adolescent; Proguanil; Double-Blind Method; Humans; Antimalarials; Treatment Outcome; Adult; Middle Aged; Aged; Animals; Indonesia; Atovaquone; Female; Drug Therapy, Combination; Drug Resistance; Malaria, Vivax; Malaria, Falciparum; Naphthoquinones; Plasmodium falciparum; Plasmodium vivax; Male